In summary, we showed that GCN5L1 could regulate oxidative metabolism and establish an inflammatory microenvironment in promoting NASH progression, which provides a potential therapeutic target for immunometabolic diseases. Here, BLOC1S1 is linked to metabolic dysfunction-associated steatohepatitis.